ACETAZOLAMIDE, a carbonic anhydrase inhibitor, has well-established teratogenic potential in rats, hamsters, and mice.1,2 According to a July 17, 1975, letter from L. Lizabeth Monroe, MD, of the Lederle Laboratories, Pearl River, NY, there is only one known case of an infant with congenital anomalies (including congenital glaucoma, microophthalmia, and patent ductus arteriosus) born to a mother treated throughout pregnancy with acetazolamide.
Report of a Case
A 22-year-old woman, gravida 2, para 0, abortus 1, was admitted to the National Naval Medical Center at 27 weeks' gestation, with spontaneous rupture of the membranes. The patient had had glaucoma since an episode of bilateral uveitis at age 13 years. She had been treated with acetazolamide, 750 mg daily, continuously since that time and had required enucleation of the left eye at age 17 years. Acetazolamide therapy was discontinued at 19 weeks' gestation. Other medications were ones without known teratogenic effects
Worsham GF, Beckman EN, Mitchell EH. Sacrococcygeal Teratoma in a Neonate: Association With Maternal Use of Acetazolamide. JAMA. 1978;240(3):251–252. doi:10.1001/jama.1978.03290030069029
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: